In the Claims:

Please cancel claim 1 without prejudice.

Please add new claims 25-37 as follows:

25. A bispecific molecule comprising an autocrine growth factor specific for a tumor cell and an antibody or antigen binding fragment thereof which binds the Fc receptor of an effector cell at a site that is not inhibited by endogenous immunoglobulin.

26. The bispecific molecule of claim 25, wherein the tumor cell is a human small-cell lung carcinoma cell.

27. The bispecific molecule of claim 26, wherein the autocrine growth factor binds to the gastrin-releasing peptide receptor of the human small-cell lung carcinoma cell.

28. The bispecific molecule of claim 27, wherein the autocrine growth factor is selected from the group consisting of bombesin and gastrin-releasing peptide and gastrin releasing peptide receptor binding analogues thereof.

29. The bispecific molecule of claim 25, wherein the Fc receptor is selected from the group consisting of FcγRI, FcγRII and FcγRIII.

30. A method of inhibiting proliferation of a tumor cell in a subject, comprising administering to the subject a bispecific molecule comprising (a) an autocrine growth factor specific for the tumor cell and (b) an antibody or an antigen binding fragment thereof which binds the Fc receptor of an effector cell at a site that is not inhibited by endogenous immunoglobulin.

31. The method of claim 30, wherein the tumor cell is a human small-cell lung carcinoma cell.

32. A method for stimulating an immune response against a tumor cell in a subject comprising administering to the subject a bispecific molecule comprising (a) an autocrine growth factor specific for the tumor cell and (b) an antibody or an antigen binding fragment thereof which binds the Fc receptor of an effector cell at a site that is not inhibited by endogenous immunoglobulin, wherein the bispecific molecule is administered in a pharmaceutically acceptable carrier.

33. The method of claim 32, wherein the autocrine growth factor is selected from the group consisting of: insulin-like growth factor I, transferrin, vasoactive intestinal peptide, neurotensin, neuromedin B, neurophysin, tumor necrosis factor, transforming growth factor alpha, platelet derived growth factor, the transferin receptor and analogues thereof.

34. The method of claim 32, wherein the autocrine growth factor is selected from the group consisting of bombesin and gastrin releasing peptide or an analogue thereof.

35. The method of claim 30, wherein the autocrine growth factor is selected from the group consisting of bombesin and gastrin releasing peptide or gastrin-releasing peptide receptor binding analogues thereof.

36. The method of claim 32, wherein the Fc receptor is selected from the group consisting of FcγRI, FcγRII and FcγRIII.

37. The method of claim 32, wherein the antibody is selected from the group consisting of: mAb22 produced by the hybridoma having ATCC Accession number HB12147 and mAb32 produced by the hybridoma having ATCC number HB9469.